Research from Roswell Park Comprehensive Cancer Center suggests a new treatment combination can extend survival for many patients with advanced colorectal cancer.
Exact Sciences, Mayo Clinic identify blood-based DNA biomarkers to diagnose hepatocellular carcinoma
Researchers at Exact Sciences Corp. and Mayo Clinic announced progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect hepatocellular carcinoma, the most common cancer that originates in the liver.
Bristol-Myers Squibb Co. announced updated results from the phase III CheckMate -238 trial evaluating Opdivo (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence following complete surgical resection.
Bristol-Myers Squibb Co. announced patient-reported outcomes data from the phase III CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the immuno-oncology combination Opdivo (nivolumab) plus low-dose (1mg/kg) Yervoy (ipilimumab) vs. sunitinib over a two-year follow-up period.
Genentech said the phase III IMpower130 study met its co-primary endpoints of overall survival and progression-free survival.
The main findings of a new analysis of the landmark Framingham Heart Study by researchers at Vanderbilt University Medical Center published May 16 by the Journal of the National Cancer Institute shows that the risk of lung cancer drops substantially within five years of quitting.
Breast cancer survivors are not getting the recommended level of screening, post-surgery, according to a study in JNCCN – Journal of the National Comprehensive Cancer Network.
MimiVax LLC announced positive interim results from a multicenter phase II study of SurVaxM in patients with newly diagnosed glioblastoma.
A national retrospective study led by researchers at MD Anderson Cancer Center found no association between intensity of post-treatment surveillance and detection of recurrence or overall survival in patients with stage I, II or III colorectal cancer. Published in the Journal of the American Medical Association, the study is the largest of surveillance intensity in CRC ever conducted.
FDA has alerted health care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1.
